Sunday, May 20, 2018
 
 
Company News: Page (1) of 1 - 02/13/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Jupiter Life Science Consulting Launches New Subscription-Based Market Research Solution for Pharma and Biotech Industries
 
(February 13, 2018)
Jupiter Life Science Consulting Launches New Subscription-Based Market Research Solution for Pharma and Biotech Industries

Jupiter Life Science Consulting, a global leader in market access and pricing strategy in the biopharmaceutical industry, today announced the launch of its payer engagement solution, Quick Qual (Q²). Jupiter's new payer intelligence service ensures pharma and biotech innovators are equipped with immediate payer insights to meet growing market access demands and optimize commercial strategies.

Through Jupiter's Q² expert panelists, representing the nation's leading national health insurance and pharmacy benefit manager organizations, Q² delivers valuable payer intelligence, quickly addressing key issues and providing time-sensitive insights enabling accelerated go-to-market strategies. The Q² panel also allows Jupiter to break from industry standard survey systems, which are often slow-moving and gather data on general topics rather than specific examples.

“Biopharma's market access environment continues to rapidly evolve, which means our clients need new solutions to remain competitive in today's market," said Steve Slovick, CEO and managing partner, Jupiter Life Science Consulting. “Biopharma stakeholders must understand how these changes impact brand access and strategy. Our Q² solution empowers the biopharma industry to avoid costly delays, as well as identify and develop comprehensive strategies that address hot-button issues in record time."



Q² Key Capabilities Include:

  • Access to a dedicated panel of payer key decision makers: Q² gathers insights from a consistent, dedicated panel of key payer decision makers from leading medical and pharmaceutical organizations representing the U.S. health care landscape.
  • Expertise in multiple focus areas: Q² can help with business development, field intelligence, brand insights, market events, launch preparation, disease-specific consultation and competitor analysis.
  • Access to flexible service offerings: Select the offering that best aligns with your organization's needs, budget and compliance demands.
  • Timely reports and summaries: Q²'s dedicated panelists work with you and your team to ensure prompt reporting that address your individualized business and compliance needs within a 72-hour timeframe.

Slovick added, “With the addition of Q², Jupiter is able to offer its clients yet another valuable tool that builds upon an arsenal of customized smart solutions designed to integrate payer and market access stakeholder insights early and often to cohesively pair price alignment to a product's value story."

For more information on Q² visit: https://jupiterls.com/payer-quick-qual/

About Jupiter Life Science Consulting
Jupiter Life Science Consulting is a global team of strategy experts with a shared passion for shaping value, navigating market access and optimizing price for pharma and biotech innovators. Jupiter's leadership has contributed to the commercial success of 75 percent of the top performing drugs in the market and operates with a shared ownership model that is unique in this industry.

Jupiter delivers proven market access, pricing and commercialization strategies, payer engagement solutions and litigation support. Jupiter equips clients to realize optimal market access through a deep understanding of stakeholder's sensitivities and deliverables that are actionable for their specific needs.

To learn more about Jupiter Life Science Consulting, visit http://www.jupiterls.com

Read the full story at http://www.prweb.com/releases/2018/02/prweb15199591.htm.


Page: 1


Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground
  • Blavatnik Family Foundation Provides $10 Million Gift to Mount Sinai to Support Mission of Advancing Women’s Health
  • Smart Contact Lenses Market 2018 Upgrading To Foster Growth At a CAGR of 10.4% | By Application; Continuous Glucose Monitoring, Intraocular Pressure Monitoring And Others Till 2023
  • Global Big Data in Healthcare Market: Analysis and Forecast, 2017-2025 (Focus on Components and Services, Applications, Competitive Landscape and Country Analysis)

    Cancer
  • Synovial Sarcoma Treatment Market, by Treatment Type Chemotherapy
  • Multiple New Vendor GPO Awards Position Keneric Healthcare to Increase Its Market Reach for Their Advanced Wound Care and Patient Cleansing Products Lines
  • RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts
  • Avicanna Inc. Proudly Hosts the "International Symposium on Cannabinoids & Medical Applications"
  • Stock-Sector Releases Interview with CEO of Helomics Discussing Precision Medicine with Precision Therapeutics
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines